Neema Reddy
Family Medicine · Eugene, ORNPI 1053416743
Payments from drug & device makers
Across 103 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$288
- Lilly USA, LLC$258
- Exact Sciences$230
- Amgen$188
- Novo Nordisk$146
- Pfizer$145
- plus $692 from 17 others
What the payments were for
- Food & beverage$1,86296%
- Education$854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $288 |
| Lilly USA, LLC | 16 | $258 |
| Exact Sciences | 11 | $230 |
| Amgen | 8 | $188 |
| Novo Nordisk | 9 | $146 |
| Pfizer | 8 | $145 |
| Boehringer Ingelheim | 5 | $93 |
| Astellas Pharma US Inc | 1 | $85 |
| Amarin Pharma, Inc. | 6 | $79 |
| Johnson & Johnson | 3 | $75 |
| Bayer | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $52 |
| Heartflow, Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| AstraZeneca | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Gilead | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Zealand Pharma US, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
How this compares
$1,947 in reported general payments places this provider in the 90th percentile of 1,221 family medicine providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $66,845 |
| JardianceEmpagliflozin | 16 | $15,267 |
| EliquisApixaban | 12 | $13,519 |
| Colesevelam Hcl | 11 | $3,447 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,606 |
| Atorvastatin Calcium | 68 | $1,276 |
| Losartan Potassium | 61 | $997 |
| Levothyroxine Sodium | 73 | $849 |
| Omeprazole | 51 | $796 |
| Potassium Chloride | 20 | $783 |
| Gabapentin | 48 | $701 |
| Metoprolol Succinate | 36 | $635 |
| Rosuvastatin Calcium | 22 | $622 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 12 | $568 |
| Dutasteride | 13 | $509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $146 | $66,84568 claims |
| Boehringer IngelheimJardiance | $93 | $15,26716 claims |
| PfizerEliquis | $145 | $13,51912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Eugene
- Patricia BuchananEugene$239K
- Hylke SniederEugene$6K
- Randy ReeseEugene$5K
- David KobliskaEugene$4K
- John DelgadoAshland$4.3M
- John MickelsonLincoln City$2.1M
- Subramaniam SeetharamanMilwaukie$1.8M
- Eden MillerBend$1.7M
- Maureen MaysPortland$491K
- Thomas TurkRoseburg$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.